Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJulia-Annabell GeorgiSSSebastian StasikMKMichael Krämer

Discussion

Loading...

Member takes

Overview

Multicenter study shows relapse risk remains high in myelofibrosis, suggesting a need for effective salvage therapy.

Key Points

  • Relapse risk remained high at 17.7% after 5 years in myelofibrosis patients post-transplant, indicating a significant concern for long-term care.
  • Cumulative incidence of relapse was 15.4% at 1 year and 27.1% at 5 years for patients undergoing allogeneic stem cell transplantation.
  • Longitudinal survival analysis and chimerism data were utilized alongside multivariate analysis based on Akaike and Bayesian Information Criteria.
  • Salvage therapy was successfully initiated in most relapsed patients, highlighting the potential of immunomodulatory strategies in treatment.

Cite This Study

Georgi et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd57https://doi.org/10.1182/blood-2025-1978
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis2025
  2. 2Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.2025
  3. 3Limitations of the IWG-MRT/ELN response criteria in defining post-transplant remission and clinical success in patients with myelofibrosis: A retrospective study2025
  4. 4Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis2025
  5. 5Peri-transplant ruxolitinib therapy significantly improves GVHD-free, relapse-free survival rates in transplantation for myelofibrosis2025 · 1 citations